Rosumore F 10 Tablet is a fixed-dose combination medication that combines Rosuvastatin, a potent statin, and Fenofibrate, a fibrate class lipid-lowering agent. This synergistic combination is specifically designed to treat mixed dyslipidemia by targeting both elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides, while improving high-density lipoprotein cholesterol (HDL-C) levels. Rosuvastatin works by inhibiting HMG-CoA reductase, reducing cholesterol synthesis in the liver, while Fenofibrate activates peroxisome proliferator-activated receptors (PPAR-alpha), enhancing the breakdown of triglyceride-rich particles. Rosumore F 10 is especially beneficial for patients with atherogenic dyslipidemia, often seen in metabolic syndrome, type 2 diabetes, or those who do not respond adequately to statin monotherapy. This tablet offers a comprehensive approach to lipid control and helps reduce the risk of atherosclerosis, coronary artery disease, stroke, and other cardiovascular events. It is usually administered once daily and is best taken under medical supervision with regular monitoring.
Common side effects may include headache, muscle pain, joint pain, nausea, abdominal discomfort, and elevated liver enzymes. Rare but serious side effects include myopathy, rhabdomyolysis, and pancreatitis, particularly when statins and fibrates are used together. Patients should be advised to report any signs of muscle tenderness, weakness, or dark-colored urine. Liver function and creatine kinase levels should be monitored periodically. Gastrointestinal disturbances or skin rash may also occur in some individuals.
Rosumore F 10 Tablet is indicated for the treatment of mixed dyslipidemia and severe hypertriglyceridemia in patients who require both LDL-C and triglyceride reduction. It is also prescribed to patients with cardiovascular risk factors, such as diabetes, hypertension, or a family history of heart disease, especially when monotherapy has proven insufficient.
Rosumore F 10 should be used under the guidance of a healthcare professional. It is contraindicated in patients with active liver disease, gallbladder disorders, severe kidney impairment, or known hypersensitivity to any of its components. The combination therapy increases the risk of muscle toxicity, particularly in elderly individuals or those with existing renal dysfunction. Alcohol should be avoided or minimized. This medication should not be used during pregnancy or breastfeeding. A lipid-lowering diet, regular physical activity, and routine laboratory monitoring are important to ensure safe and effective therapy.
Store Rosumore F 10 Tablet in a cool and dry place, preferably below 30°C. Protect the medication from moisture and direct sunlight. Keep out of reach of children. Do not use the medicine after its expiry date.